Effects of polymorphism in Promoter Region of Human CYP2A6 Gene (CYP2A6*9) on Expression Level of Messenger Ribonucleic Acid and Enzymatic Activity In Vivo and In Vitro

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Clinical pharmacology and therapy

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0009-9236(03)00090-0PMID 12844137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences

  2002cited by this paper
• INTERINDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM AND GENETIC POLYMORPHISMS OF HUMAN CYP2A6

  2002cited by this paper
• An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.

  2002cited by this paper
• A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.

  2002cited by this paper
• Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

  2002cited by this paper
• Nicotine metabolism and CYP2A6 allele frequencies in Koreans.

  2001cited by this paper
• CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic Activity*

  2001cited by this paper
• Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

  2001cited by this paper
• Deficient C‐oxidation of nicotine continued

  2001cited by this paper
• A novel single nucleotide polymorphism altering stability and activity of CYP2a6.

  2001cited by this paper
• Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans

  2001cited by this paper
• Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.

  2000cited by this paper
• Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography.

  2000cited by this paper
• Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans

  2000cited by this paper
• CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians

  2000cited by this paper
• Expression of CYP2A genes in human liver and extrahepatic tissues.

  1999cited by this paper
• CYP2A6 gene deletion reduces susceptibility to lung cancer.

  1999cited by this paper
• Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism

  1999cited by this paper
• Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype.

  1999cited by this paper
• Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.

  1999cited by this paper
• Characterisation and PCR‐based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population

  1999cited by this paper
• A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

  1998cited by this paper
• Nicotine metabolism defect reduces smoking

  1998cited by this paper
• Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.

  1996cited by this paper
• A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.

  1995cited by this paper
• Direct molecular identification of the mouse pink-eyed unstable mutation by genome scanning.

  1991cited by this paper
• The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

  1990cited by this paper
• Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction.

  1988cited by this paper
• Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats

  1973cited by this paper
• Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats.

  1973cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Genetic variations in CYP2A6 predict efficacy of neoadjuvant letrozole concurrent with chemotherapy in locally advanced hormone receptor-positive breast cancer

  2025cites this paper
• Pharmacokinetics and bioequivalence of two formulations of the S-1 (tegafur/gimeracil/oxonate) capsule in Chinese cancer patients under fasting and fed conditions: a multicenter, randomized, open-label, single-dose, double-cycle crossover study

  2025cites this paper
• Effect of Liver Dysfunction on S-1 Therapy Induced Adverse Effects: A Retrospective Cohort Study

  2024cites this paper
• PharmVar GeneFocus: CYP2A6

  2024cites this paper
• Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers

  2022cites this paper
• Alcohol and Nicotine Use among Adolescents: An Observational Study in a Sicilian Cohort of High School Students

  2022cites this paper
• Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome

  2021cites this paper
• Cytochrome P450 expression and regulation in the brain

  2020cites this paper
• Nicotine in Senescence and Atherosclerosis

  2020cites this paper
• Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors

  2020cites this paper
• Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism

  2020cites this paper
• The Role of Flavors in Electronic Cigarette Abuse Liability in Tobacco-Naïve Young Adults

  2020cites this paper
• Association between CYP2A6 genotypes and smoking behavior in Lebanese smokers

  2020cites this paper
• Associations of CYP2A6 Gene Polymorphism with Smoking Status among Jordanians: Gender-Related Differences.

  2019cites this paper
• From Genotype to Phenotype: Content and Activities of Cytochromes P450 2A6 in Human Liver In Vitro and Predicted In Vivo

  2019cites this paper
• Pharmacogenomics of nicotine metabolism: novel CYP2A6 and CYP2B6 genetic variation patterns in Alaska Native and American Indian populations.

  2019cites this paper
• Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model

  2018cites this paper
• Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs

  2018cites this paper
• Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 2A6 in a Tibetan Chinese population.

  2018cites this paper
• Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.

  2018cites this paper
• Introduction to Human Cytochrome P450 Superfamily

  2018cites this paper
• Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.

  2017cites this paper
• Relationship between metabolic phenotypes and genotypes of CYP1A2 and CYP2A6 in the Nigerian population

  2017cites this paper
• Multimodal Therapies for Upper Gastrointestinal Cancers – Past, Now, and Future

  2017cites this paper
• Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction

  2017cites this paper
• Title Comprehensive evaluation of variability in nicotine metabolism andCYP 2 A 6 polymorphic alleles in four ethnic populations

  2017cites this paper
• Inter-Individual Variability of Cytochrome P450 2A6 Activity in Javanese Smokers’ Urine

  2017cites this paper
• Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio

  2016cites this paper
• Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis

  2016cites this paper
• Genetic Aspects of Smoking Behavior in the Japanese Population

  2016cites this paper
• Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes.

  2016cites this paper
• Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis

  2016cites this paper
• Genetic Risk Determinants for Cigarette Smoking Dependence in Mexican Mestizo Families.

  2016cites this paper
• Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo

  2015cites this paper
• Emerging role of S-1 in gastric cancer

  2015cites this paper
• Identification and Characterization of Novel CYP2A6 Variants in African American Slow Nicotine Metabolizers

  2014cites this paper
• Effect of CYP2A6 Genetic Polymorphism on the Metabolic Conversion of Tegafur to 5-Fluorouracil and Its Enantioselectivity

  2014cites this paper
• Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.

  2014cites this paper
• Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

  2014cites this paper
• Single tube genotyping of CYP2A6 gene deletion based on copy number determination by quantitative real-time PCR.

  2014cites this paper
• 2-13C-Uracil 呼気テストによるS-1 感受性予測

  2014cites this paper
• Efficacy of S-1 in colorectal cancer

  2014cites this paper
• The Pharmacogenetics of Nicotine Dependence and Smoking Cessation Therapies

  2014cites this paper
• The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans

  2013cites this paper
• Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma

  2013cites this paper
• Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.

  2013cites this paper
• Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.

  2013cites this paper
• A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele

  2013cites this paper
• Advances in molecular modeling of human cytochrome P450 polymorphism.

  2013cites this paper
• Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective

  2013cites this paper
• A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

  2012cites this paper
• 7 Nicotine Dependence

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6

  2012cites this paper
• Change of TATA-binding protein affinity to oligonucleotides corresponding to TATA boxes in human gene promoters bearing polymorphisms associated with hereditary diseases

  2012influential citation
• Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.

  2012cites this paper
• PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8

  2012cites this paper
• Importance of pharmacogenetic and environmental factors for variation in caffeine disposition: with special emphasis on CYP1A2, CYP2A6, NAT2 and XO

  2012cites this paper
• Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.

  2012cites this paper
• Associations of CYP2A6 genotype with smoking behaviors in southern China.

  2011cites this paper
• Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.

  2011cites this paper
• Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.

  2011cites this paper
• Phase I trial of chemoradiotherapy with the combination of S‐1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck

  2011cites this paper
• Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients

  2011cites this paper
• CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients

  2011influential citation
• CYP2A6 and CYP2B6 Genetic Variation, and Tobacco Use Behaviours and Biomarkers in Alaska Natives

  2011influential citation
• Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations

  2011cites this paper
• Multimodal Therapies for Upper Gastrointestinal Cancers – Past, Now, and Future

  2011cites this paper
• The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European–Americans

  2011cites this paper
• Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer

  2010cites this paper
• Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.

  2010cites this paper
• Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?

  2010cites this paper
• CYP2A6 gene polymorphisms impact to nicotine metabolism

  2010cites this paper
• The genetic aspects of nicotine metabolism and their impact on adolescent nicotine dependence

  2010cites this paper
• An investigation of nicotine metabolism in mice : the impact of pharmacological inhibition and genetic influences on nicotine pharmacology.

  2010influential citation
• The Impact of CYP2A6 Genotype on Smoking Cessation in an Extended Nicotine Patch Therapy Clinical Trial

  2010influential citation
• Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer

  2009cites this paper
• In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

  2009cites this paper
• Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer.

  2009cites this paper
• Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population.

  2009cites this paper
• Pharmacogenetics of smoking cessation therapy

  2009cites this paper
• CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking

  2009cites this paper
• High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population.

  2009influential citation
• Prediction of S-1-induced anemia

  2009cites this paper
• Nicotine contents in various toothpowders (dant manjans): measurement and safety evaluation.

  2009cites this paper
• Structure, function, regulation and polymorphism of human cytochrome P450 2A6.

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Molecular genetics of nicotine metabolism.

  2009cites this paper
• 2 Humans 2 . 1 Human Nicotine Metabolism

  2009cites this paper
• CYP2A6 allele frequencies in an Iranian population.

  2008cites this paper
• Revealing the paradox of drug reward in human evolution

  2008influential citation
• Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy

  2008cites this paper
• Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition

  2008cites this paper
• Untersuchung der Nikotinkinetik in Abhängigkeit von biologischen und rauchanamnestischen Variablen

  2008cites this paper
• CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1

  2008cites this paper
• CYP2A6 polymorphisms and risk for tobacco-related cancers.

  2008cites this paper
• Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine

  2008cites this paper
• Response to “The Unanswered Question: What Is the Determinant of S‐1 Pharmacokinetics?”

  2008cites this paper
• The CYP2A6*4 Allele Is Determinant of S‐1 Pharmacokinetics in Japanese Patients With Non‐small‐cell Lung Cancer

  2008cites this paper
• Search for functional alleles in the human genome with focus on cardiovascular disease candidate genes.

  2007cites this paper
• Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children.

  2007cites this paper